RA Capital Management L.P. Takes $5.97 Million Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

RA Capital Management L.P. acquired a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,038,000 shares of the biotechnology company's stock, valued at approximately $5,968,000. RA Capital Management L.P. owned approximately 4.87% of Enanta Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its position in Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 2,274 shares during the last quarter. AlphaQuest LLC raised its stake in shares of Enanta Pharmaceuticals by 16.4% during the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock worth $128,000 after purchasing an additional 3,137 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Enanta Pharmaceuticals by 7.3% in the 4th quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company's stock valued at $268,000 after buying an additional 3,186 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Enanta Pharmaceuticals by 10.5% in the fourth quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company's stock valued at $213,000 after buying an additional 3,501 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $26,000. Institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Stock Down 1.7 %

Shares of ENTA traded down $0.10 during trading hours on Friday, hitting $5.95. The company had a trading volume of 101,428 shares, compared to its average volume of 287,070. The business has a fifty day moving average of $5.91 and a 200-day moving average of $7.10. The firm has a market cap of $126.93 million, a price-to-earnings ratio of -1.20 and a beta of 0.81. Enanta Pharmaceuticals, Inc. has a 12 month low of $4.09 and a 12 month high of $17.24.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. On average, equities analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on ENTA shares. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. JMP Securities reiterated a "market outperform" rating and set a $21.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, StockNews.com raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $17.25.

Insider Activity at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly bought 45,000 shares of the company's stock in a transaction dated Wednesday, February 12th. The stock was bought at an average price of $5.69 per share, with a total value of $256,050.00. Following the completion of the acquisition, the chief executive officer now owns 846,638 shares of the company's stock, valued at $4,817,370.22. This represents a 5.61 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 13.89% of the stock is currently owned by corporate insiders.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.